A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SGB-9768 in Patients with Primary IgA Nephropathy, C3 Glomerulopathy, and Immune Complex-mediated Membranoproliferative Glomerulonephritis.
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs SGB 9768 (Primary)
- Indications IgA nephropathy; Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Sponsors SanegeneBio
- 29 Jan 2025 New trial record